AR131380A1 - Purinas 2,6,9-trisustituidas - Google Patents

Purinas 2,6,9-trisustituidas

Info

Publication number
AR131380A1
AR131380A1 ARP230103410A ARP230103410A AR131380A1 AR 131380 A1 AR131380 A1 AR 131380A1 AR P230103410 A ARP230103410 A AR P230103410A AR P230103410 A ARP230103410 A AR P230103410A AR 131380 A1 AR131380 A1 AR 131380A1
Authority
AR
Argentina
Prior art keywords
compounds
salts
trisubstituted purines
trisubstituted
purines
Prior art date
Application number
ARP230103410A
Other languages
English (en)
Inventor
Bernard Barlaam
Michael Bodnarchuk
Frederick Goldberg
Avipsa Ghosh
Sudhir Hande
Phillip Lichtor
Kun Song
Qibin Su
Reem Telmesani
James Sheppeck
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR131380A1 publication Critical patent/AR131380A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos que tienen la estructura de fórmula (1) y sales farmacéuticamente aceptables de la misma, en donde R¹, R², R³, R⁴, y R⁵ son como se define en la especificación; composiciones farmacéuticas que comprenden estos compuestos y sales; uso de estos compuestos y sales para tratar o prevenir condiciones mediadas por cinasa 2 dependiente de ciclina (CDK2); kits que comprenden estos compuestos y sales; y métodos para fabricar estos compuestos y sales.
ARP230103410A 2022-12-16 2023-12-15 Purinas 2,6,9-trisustituidas AR131380A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263387734P 2022-12-16 2022-12-16

Publications (1)

Publication Number Publication Date
AR131380A1 true AR131380A1 (es) 2025-03-12

Family

ID=89473830

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230103410A AR131380A1 (es) 2022-12-16 2023-12-15 Purinas 2,6,9-trisustituidas

Country Status (17)

Country Link
US (2) US20240247001A1 (es)
EP (1) EP4634186A1 (es)
JP (1) JP2026500305A (es)
KR (1) KR20250121114A (es)
CN (1) CN120359223A (es)
AR (1) AR131380A1 (es)
AU (1) AU2023393410A1 (es)
CL (1) CL2025001706A1 (es)
CO (1) CO2025009649A2 (es)
CR (1) CR20250283A (es)
DO (1) DOP2025000143A (es)
IL (1) IL321433A (es)
MX (1) MX2025006884A (es)
PE (1) PE20251925A1 (es)
TW (1) TWI922868B (es)
UY (1) UY40564A (es)
WO (1) WO2024127350A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025202991A1 (en) * 2024-03-29 2025-10-02 Astrazeneca Ab Crystalline form of (s)-n-ethyl-3-((9-ethyl-2-(((2r,3s)-2-hydroxypentan-3-yl)amino)-9h-purin-6-yl)amino)-pyrrolidine-1-sulfonamide
WO2026012471A1 (zh) * 2024-07-11 2026-01-15 上海先声再明医药生物科技有限公司 取代嘌呤类化合物及其应用
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
CN119462661A (zh) * 2024-09-24 2025-02-18 烟台皓元生物医药科技有限公司 一种azd-8421及其中间体的制备方法

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432164A (en) 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
AU2022497A (en) 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
GB9723589D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
IL144675A0 (en) 1999-02-01 2002-05-23 Cv Therapeutics Inc PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2793794B1 (fr) 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
CZ2002961A3 (cs) 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
EP1377579B1 (en) 2000-10-31 2009-03-25 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US20060009642A1 (en) 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
CA2463563A1 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
AU2002334992B2 (en) 2001-10-12 2009-07-02 Irm Llc Methods for the synthesis of substituted purines
JP2005535631A (ja) 2002-06-27 2005-11-24 エフ.ホフマン−ラ ロシュ アーゲー プリン誘導体の合成
WO2004069185A2 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
WO2005020892A2 (en) 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
JP2007502776A (ja) 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Rtk阻害剤としての6−置換アニリノプリン類
MXPA06013250A (es) 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
JP2006056879A (ja) 2004-07-21 2006-03-02 Kobe Univ インスリン抵抗性の改善剤、及びそのスクリーニング方法
US7514417B2 (en) 2005-05-19 2009-04-07 Cv Therapeutics, Inc. A1 adenosine receptor agonists
BRPI0614502A2 (pt) 2005-07-30 2011-03-29 Astrazeneca Ab Composto, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto
WO2007028022A2 (en) 2005-09-01 2007-03-08 Renovis, Inc. Novel compounds as p2x7 modulators and uses thereof
GB0606283D0 (en) 2006-03-29 2006-05-10 Cyclacel Ltd Process
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
CA2676138A1 (en) 2007-01-26 2008-08-07 Irm Llc Compounds and compositions as kinase inhibitors
GB0706632D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009034386A1 (en) 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
WO2009129094A2 (en) 2008-04-15 2009-10-22 Mallinckrodt Inc. Compositions containing antiviral compounds and methods of using the same
EP2303881A2 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
US8377639B2 (en) 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
US20130137728A1 (en) 2010-03-24 2013-05-30 MUSC Foundation for Research and Development Compositions and Methods for the Treatment of Degenerative Diseases
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
WO2012019093A1 (en) 2010-08-05 2012-02-09 Human Biomolecular Research Institute Synthetic compounds and methods to decrease nicotine self-administration
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
US9133164B2 (en) 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
DK2753605T3 (da) 2011-09-09 2019-06-17 Lantheus Medical Imaging Inc Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler
US9187480B2 (en) 2012-02-17 2015-11-17 Research Triangle Institute Peripherally restricted diphenyl purine derivatives
RU2661896C2 (ru) 2012-11-16 2018-07-23 Мерк Шарп И Доум Корп. Пуриновые ингибиторы фосфатидилинозитол-3-киназы дельта человека
US20140275178A1 (en) 2013-03-13 2014-09-18 Musc Foundation For Research Development Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
WO2014172616A2 (en) 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
US9796714B2 (en) 2013-05-20 2017-10-24 University of Pittsburgh—of the Commonwealth System of Higher Education Calcium channel agonists
WO2016011394A1 (en) 2014-07-18 2016-01-21 The General Hospital Corporation Imaging agents for neural flux
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
US20180000814A1 (en) 2016-06-14 2018-01-04 Joseph Hacia Compositions and methods for the treatment of zellweger spectrum disorder
WO2018036414A1 (zh) 2016-08-23 2018-03-01 北京诺诚健华医药科技有限公司 稠杂环类衍生物、其制备方法及其在医学上的应用
KR101893879B1 (ko) 2017-03-31 2018-09-03 한국화학연구원 신규한 cdk 저해 화합물, 이의 제조방법, 및 이를 유효성분으로 함유하는 cdk 관련 질환의 예방 또는 치료용 약학적 조성물
US20190029977A1 (en) 2017-04-24 2019-01-31 Mercaptor Discoveries, Inc. Use of Thiol Compounds to Treat Neurological Disease
CN110582496A (zh) 2017-05-03 2019-12-17 格勒诺布尔-阿尔卑斯大学 用于合成多样取代的嘌呤的方法
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
JP2021536458A (ja) 2018-09-04 2021-12-27 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. アリール炭化水素レセプター・アンタゴニスト及び使用方法
JP2022506682A (ja) 2018-11-05 2022-01-17 アビスタ ファーマ ソリューションズ,インコーポレーテッド 化合物
JP7594787B2 (ja) 2018-12-07 2024-12-05 ユニバーシティ オブ メリーランド、ボルチモア 非ATP/触媒部位p38マイトジェン活性化プロテインキナーゼ阻害剤
CA3128155C (en) 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
CN113692276B (zh) 2019-02-19 2026-02-27 加利福尼亚大学董事会 Nurr1受体调节剂
WO2020181050A1 (en) 2019-03-05 2020-09-10 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
CN111825674A (zh) 2019-04-22 2020-10-27 上海仕谱生物科技有限公司 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
CN114025758B (zh) 2019-07-01 2026-05-08 钱立刚 P2x7r拮抗剂
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CN113024563B (zh) 2019-12-24 2023-01-03 药康众拓(江苏)医药科技有限公司 嘧啶并五元杂环类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途
US20230140941A1 (en) 2020-03-13 2023-05-11 University Of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
US12653888B2 (en) 2020-05-04 2026-06-16 Sigilon Therapeutics, Inc. Compositions, devices and methods for inducing immune responses to infectious agents
JP7853532B2 (ja) 2020-05-19 2026-04-30 ファーマコスモス ホールディング エー/エス 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
US20260167619A2 (en) 2020-09-22 2026-06-18 Beone Medicines I Gmbh Indoline compounds and derivatives as egfr inhibitors
CN122562781A (zh) 2020-10-07 2026-08-14 上海睿跃生物科技有限公司 治疗癌症的化合物和方法
EP4284415A4 (en) 2021-01-26 2024-12-11 Sigilon Therapeutics, Inc. BIOCOMPATIBLE DEVICES FOR CELL-BASED THERAPIES AND RELATED METHODS
CN116981473A (zh) 2021-01-26 2023-10-31 西吉隆医疗股份有限公司 用于治疗免疫介导的炎性疾病的组合物、装置和方法
US20240374507A1 (en) 2021-01-26 2024-11-14 Sigilon Therapeutics, Inc. Compositions, devices and methods for inducing antigen-specific immune tolerance
WO2022266190A1 (en) 2021-06-16 2022-12-22 Blueprint Medicines Corporation Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors
CN117897384A (zh) 2021-06-28 2024-04-16 缆图药品公司 Cdk2抑制剂
CN116813621A (zh) 2023-06-08 2023-09-29 江南大学 9h嘌呤类化合物及其药物组合物和用途

Also Published As

Publication number Publication date
EP4634186A1 (en) 2025-10-22
WO2024127350A1 (en) 2024-06-20
TWI922868B (zh) 2026-04-21
KR20250121114A (ko) 2025-08-11
US20240247001A1 (en) 2024-07-25
JP2026500305A (ja) 2026-01-06
PE20251925A1 (es) 2025-08-05
CN120359223A (zh) 2025-07-22
US12441744B2 (en) 2025-10-14
MX2025006884A (es) 2025-07-01
UY40564A (es) 2024-06-28
IL321433A (en) 2025-08-01
CO2025009649A2 (es) 2025-08-08
TW202440578A (zh) 2024-10-16
CR20250283A (es) 2025-08-21
CL2025001706A1 (es) 2025-08-18
US20250197425A1 (en) 2025-06-19
DOP2025000143A (es) 2025-08-15
AU2023393410A1 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
UY40564A (es) Purinas 2,6,9-trisustituidas
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
MX2021014096A (es) Compuestos heterociclicos, metodos de preparacion y usos de estos.
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
BR112019012217A2 (pt) compostos de amino-triazolopiridina e seu uso no tratamento de câncer
BRPI0408068A (pt) derivados de 5-feniltiazol e seus usos como inibidores de pi3 cinase
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
CY1116281T1 (el) Ιμιδαζο[4,5-c]κινολινες ως αναστολεις dna-pk
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
CO5700751A2 (es) Derivados de 4-(6-cloro-2,3-metilendioxianilino)-7 (alcoxi sustituiidos)-5-tetrahidropiran-4-iloxiquinazolina como inhibidores de la enzima tirosina quinasa no receptora y composiciones que los contienen
UY27742A1 (es) Derivados de quinazolina
MX2017000806A (es) Derivados de 2-h-indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos.
UY32059A (es) Compuestos de pirrolo [2,3-d] pirimidina
CR9663A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
CO2021006114A2 (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer
AR072622A1 (es) Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas
AR059320A1 (es) Composicion antitumorial que comprende un inhibidor de quinasas dependientes de ciclinas y un anticuerpo que inhibe un factor de crecimiento y/o un compuesto antimitotico
MX2025001108A (es) Inhibidores de cinasas aminoheteroarílicos.
UY27452A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
BR112022022452A2 (pt) Inibidores de il4i1 e métodos de uso
BR112023005005A2 (pt) Inibidores não covalentes da cinase 7 dependente de ciclina (cdk7)
MX2024010321A (es) Inhibidores de la quinasa tipo polo 4 (plk4), composiciones farmaceuticas, metodos de preparacion y usos de los mismos
AR128842A1 (es) Pirimidinas para degradar la tirosina quinasa de bruton
DOP2025000197A (es) Inhibidores de quinasa dependientes de ciclina (cdk2)
BR112022001158A2 (pt) Derivados de 4-(imidazo[1,2-a]piridin-3-il)-pirimidina